Association between thiopurine medication exposure and Alzheimer's disease among a cohort of patients with inflammatory bowel disease

S Scott Sutton; Joseph Magagnoli; Tammy Cummings; James W Hardin

doi:10.1016/j.trci.2019.10.002

Association between thiopurine medication exposure and Alzheimer's disease among a cohort of patients with inflammatory bowel disease

Alzheimers Dement (N Y). 2019 Nov 20:5:809-813. doi: 10.1016/j.trci.2019.10.002. eCollection 2019.

Authors

S Scott Sutton¹, Joseph Magagnoli¹, Tammy Cummings², James W Hardin³

Affiliations

¹ Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, College of Pharmacy, Columbia, SC, USA.
² Dorn Research Institute, WJB Dorn Veterans Affairs Medical Center, Columbia, SC, USA.
³ Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, SC, USA.

Abstract

Introduction: Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of the Rho-GTPase family of proteins, could be an Alzheimer's disease (AD) triggering co-factor due to its effect on both amyloid precursor protein (APP) and tau. Thiopurine medications, such as azathioprine and mercaptopurine, are immunosuppressants that suppress Rac1 activation. We hypothesize that due to their ability to suppress Rac1, thiopurines are associated with a lower risk of AD.

Methods: To explore the relationship between thiopurines and incident AD diagnosis, we conducted a national retrospective cohort study among U.S. Veterans with inflammatory bowel disease (IBD), including Crohn's disease (CD) or ulcerative colitis (UC), as well as a non-IBD control. We created propensity score-matched cohorts and estimated the hazard ratio via the time-dependent Cox proportional hazards model.

Results: The study sample size was 66,312 patients and consisted of 24,057 IBD patients (4354 thiopurine exposed and 19,703 unexposed) and 42,255 patients without IBD or thiopurine exposure. Patients exposed to thiopurines have the lowest rate of AD, and our results demonstrate for each additional year of thiopurine exposure risk of AD is reduced by 8.3%% (adjusted HR = 0.917; 95% CI = [0.851-0.989]).

Discussion: Our results support the preclinical findings implicating Rac1 in the AD disease process. A national cohort study demonstrated that Rac1 is associated with the AD process consistent with the preclinical evidence. Further exploration and evaluation of Rac1 inhibition are needed.